Skip to main content
IDWeek 2021 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
View Session ViewAttendees 63

Adult ID

Pediatric ID

Trainee

Transplant
Interactive Session

90 - Therapeutic options for MDR gram-negatives

Friday, October 1, 2021
2:45 PM - 4:00 PM EDT

    Interactive Moderator(s)

  • Yohei Doi, MD, PHD

    Professor of Medicine
    Division of Infectious Diseases
    University of Pittsburgh
    Pittsburgh, PA, United States

    Astellas (Individual(s) Involved: Self): Grant/Research Support; AstraZeneca (Individual(s) Involved: Self): Speakers' bureau; bioMerieux (Individual(s) Involved: Self): Consultant, Speakers' bureau; Chugai (Individual(s) Involved: Self): Consultant; Entasis (Individual(s) Involved: Self): Consultant; FujiFilm (Individual(s) Involved: Self): Advisor or Review Panel member; Gilead (Individual(s) Involved: Self): Consultant; GSK (Individual(s) Involved: Self): Consultant; Kanto Chemical (Individual(s) Involved: Self): Grant/Research Support; MSD (Individual(s) Involved: Self): Speaking Fee; Pfizer (Individual(s) Involved: Self): Grant/Research Support; Shionogi (Individual(s) Involved: Self): Grant/Research Support, Speakers' bureau; Teijin Healthcare (Individual(s) Involved: Self): Speakers' bureau; VenatoRx (Individual(s) Involved: Self): Consultant

  • Truc Cecilia Tran, PharmD

    Assistant Professor
    UTHealth McGovern Medical School
    Houston, Texas, United States

    I do not have any relevant financial / non-financial relationships with any proprietary interests.

    • Panelist(s)

  • Jason Gallagher, PharmD, FIDP, FCCP, FIDSA, BCPS

    Clinical Professor
    Temple University
    Philadelphia, PA, United States

    Astellas (Individual(s) Involved: Self): Speakers' bureau; Merck (Individual(s) Involved: Self): Consultant, Grant/Research Support; Nabriva: Consultant; Qpex (Individual(s) Involved: Self): Consultant; Shionogi (Individual(s) Involved: Self): Consultant

  • David van Duin, MD, PhD

    Professor of Medicine
    University of North Carolina
    Chapel Hill, NC, United States

    I do not have any relevant financial / non-financial relationships with any proprietary interests.

  • Ana Gales, MD, PhD

    Full professor of Infectious Diseases
    Universidade Federal de São Paulo
    Braganca Paulista, Sao Paulo, Brazil

    EUROFARMA (Individual(s) Involved: Self): Consultant, Grant/Research Support; MSD (Individual(s) Involved: Self): Consultant, Grant/Research Support, Scientific Research Study Investigator; PFIZER (Individual(s) Involved: Self): Consultant, Scientific Research Study Investigator

Participants should be aware of the following financial/non-financial relationships:
Yohei Doi, MD, PhD: Astellas (Individual(s) Involved: Self): Grant/Research Support; AstraZeneca (Individual(s) Involved: Self): Speakers' bureau; bioMerieux (Individual(s) Involved: Self): Consultant, Speakers' bureau; Chugai (Individual(s) Involved: Self): Consultant; Entasis (Individual(s) Involved: Self): Consultant; FujiFilm (Individual(s) Involved: Self): Advisor or Review Panel member; Gilead (Individual(s) Involved: Self): Consultant; GSK (Individual(s) Involved: Self): Consultant; Kanto Chemical (Individual(s) Involved: Self): Grant/Research Support; MSD (Individual(s) Involved: Self): Speaking Fee; Pfizer (Individual(s) Involved: Self): Grant/Research Support; Shionogi (Individual(s) Involved: Self): Grant/Research Support, Speakers' bureau; Teijin Healthcare (Individual(s) Involved: Self): Speakers' bureau; VenatoRx (Individual(s) Involved: Self): Consultant
Truc Cecilia Tran, PharmD: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Jason C. Gallagher, PharmD, FIDP, FCCP, FIDSA, BCPS: Astellas (Individual(s) Involved: Self): Speakers' bureau; Merck (Individual(s) Involved: Self): Consultant, Grant/Research Support; Nabriva: Consultant; Qpex (Individual(s) Involved: Self): Consultant; Shionogi (Individual(s) Involved: Self): Consultant
David van Duin, MD, PhD: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Ana C. Gales, MD, PhD: EUROFARMA (Individual(s) Involved: Self): Consultant, Grant/Research Support; MSD (Individual(s) Involved: Self): Consultant, Grant/Research Support, Scientific Research Study Investigator; PFIZER (Individual(s) Involved: Self): Consultant, Scientific Research Study Investigator

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
ACPE Credits: ACPE 1.25 Knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-0000-21-001-H01-P

Learning Objectives:

At the conclusion of this session, participants will be able to:
  • discuss the clinical and therapeutic approach of infections caused by multidrug-resistant Gram negative organisms
  • assess the clinical relevant data supporting the use of new antimicrobials against infections caused by multidrug-resistant Gram negative organisms
  • review relevant mechanisms of antimicrobial resistance and their influence in the selection of antimicrobials